Shanghai ZJ Bio-Tech Co. Ltd. A Cash Flow Conversion Efficiency

Latest as of September 2025: 0.002x

Shanghai ZJ Bio-Tech Co. Ltd. A cash flow conversion efficiency. Based on the latest financial reports, Shanghai ZJ Bio-Tech Co. Ltd. A (688317) has a cash flow conversion efficiency ratio of 0.002x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥6.85 Million ≈ $1.00 Million USD) by net assets (CN¥3.39 Billion ≈ $496.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Shanghai ZJ Bio-Tech Co. Ltd. A (2013–2025)

Cash flow conversion efficiency of Shanghai ZJ Bio-Tech Co. Ltd. A from 2013 to 2025. This chart illustrates how Shanghai ZJ Bio-Tech Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 688317 share price today for real-time trading data and today's change.

Shanghai ZJ Bio-Tech Co. Ltd. A Cash Flow Conversion Ratio Explained

Shanghai ZJ Bio-Tech Co. Ltd. A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Shanghai ZJ Bio-Tech Co. Ltd. A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Shanghai ZJ Bio-Tech Co. Ltd. A ranked by their cash flow conversion efficiency. Also see Shanghai ZJ Bio-Tech Co. Ltd. A (688317) market capitalisation for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Shinhan Alpha REIT Co Ltd
KO:293940
0.005x
Yieh United Steel
TWO:9957
-0.055x
Guggenheim Active Allocation Fund
NYSE:GUG
N/A
Concord Securities Co Ltd
TWO:6016
-0.162x
One Liberty Properties Inc
NYSE:OLP
0.015x
RPG Life Sciences Limited
NSE:RPGLIFE
0.019x
Hanssem
KO:009240
0.096x
Zhongrui Co Ltd
SHE:301587
0.017x

Annual Cash Flow Conversion Efficiency for Shanghai ZJ Bio-Tech Co. Ltd. A (2013–2025)

The table below shows the annual cash flow conversion efficiency of Shanghai ZJ Bio-Tech Co. Ltd. A from 2013 to 2025. Review Shanghai ZJ Bio-Tech Co. Ltd. A (688317) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥3.35 Billion
≈ $490.04 Million
CN¥66.85 Million
≈ $9.78 Million
0.020x -6.43%
2024-12-31 CN¥3.64 Billion
≈ $532.19 Million
CN¥77.59 Million
≈ $11.35 Million
0.021x +199.65%
2023-12-31 CN¥3.82 Billion
≈ $559.71 Million
CN¥-81.88 Million
≈ $-11.98 Million
-0.021x -115.37%
2022-12-31 CN¥4.20 Billion
≈ $614.65 Million
CN¥584.97 Million
≈ $85.60 Million
0.139x -16.97%
2021-12-31 CN¥3.83 Billion
≈ $560.07 Million
CN¥641.94 Million
≈ $93.94 Million
0.168x -78.52%
2020-12-31 CN¥1.46 Billion
≈ $214.02 Million
CN¥1.14 Billion
≈ $167.08 Million
0.781x +482.33%
2019-12-31 CN¥571.84 Million
≈ $83.68 Million
CN¥76.66 Million
≈ $11.22 Million
0.134x -11.44%
2018-12-31 CN¥532.66 Million
≈ $77.95 Million
CN¥80.63 Million
≈ $11.80 Million
0.151x +49.06%
2017-12-31 CN¥472.70 Million
≈ $69.17 Million
CN¥48.00 Million
≈ $7.02 Million
0.102x +10.36%
2016-12-31 CN¥483.90 Million
≈ $70.81 Million
CN¥44.53 Million
≈ $6.52 Million
0.092x +147.38%
2015-12-31 CN¥343.47 Million
≈ $50.26 Million
CN¥12.78 Million
≈ $1.87 Million
0.037x -85.11%
2014-12-31 CN¥110.35 Million
≈ $16.15 Million
CN¥27.57 Million
≈ $4.03 Million
0.250x +4.71%
2013-12-31 CN¥118.03 Million
≈ $17.27 Million
CN¥28.16 Million
≈ $4.12 Million
0.239x --

About Shanghai ZJ Bio-Tech Co. Ltd. A

SHG:688317 China Medical Devices
Market Cap
$456.98 Million
CN¥3.12 Billion CNY
Market Cap Rank
#12367 Global
#3600 in China
Share Price
CN¥16.45
Change (1 day)
-2.03%
52-Week Range
CN¥15.05 - CN¥26.37
All Time High
CN¥80.15
About

Shanghai ZJ Bio-Tech Co., Ltd. engages in the research and development, production, and sale of molecular diagnostic reagents and instruments in China and internationally. The company offers nucleic acid and real-time PCR kits, as well as consumables. It serves public health safety and clinical diagnostics sectors. The company was founded in 2005 and is based in Shanghai, China.